Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Discovering HIV & AIDS genetic variants
- Heterogeneity in the HIV epidemic
- Natural history of HIV
- Candidate gene association studies
- Genotype-phenotype associations
- Genetic models
- CCR5 is a co-receptor for primary isolates of HIV
- HIV cell entry
- Consequence of Δ32 on the CCR5 protein
- CCR5 Δ32 allele and genotype frequencies
- CCR5 Δ32 homozygous individuals
- CCR5 ∆32 effect on progression to AIDS
- Trajectory of CD4 loss over time
- Summary (CCR5 ∆32)
- Bench to bedside translation
- HIV-1 life cycle: chemokine-receptor nexus
- HIV life cycle and points of restriction (1)
- PPIA promoter SNP
- HIV life cycle and points of restriction (2)
- Effects of post-entry factors on progression
- Summary (other factors)
- Immune surveillance for viral pathogens
- HLA gene classes
- HLA-B27 protects against HIV progression
- HLA candidate gene associations
- Host & viruses evolving arms race
- KIR regulate NK cell activity
- KIR genes
- Epistatic effect of KIR3DS1 & HLA-Bw4-80I
- KIRxHLA interaction effect on AIDS-free survival
- Genome wide association study (GWAS) era
- GWAS success
- Whole genome-wide association study
- Quantile-quantile plot
- Manhattan plot
- GWAS publications
- First HIV GWAS
- Two SNPs determinants of viral set point
- CD4<350 or ART initiation association with time
- Increasing statistical power
- Controller study data
- Novel associations
- Controlling HIV level vs. maintaining CD4 level
- Long term non-progressors
- Non-HLA and CCR5/2 associations from GWAS
- HIV acquisition
- HIV-related conditions
- C22 and HIV-associated nephropathy
- APOL1 risk alleles and sleeping sickness
- Summary (GWAS)
- Summary (final)
- Future directions: a systems-based approach
- Acknowledgements and disclaimers
Topics Covered
- Overview of candidate gene association studies of HIV and AIDS
- Key role for genetic variants involved in cell entry and host defenses
- Homozygous CCR5 32 basepair deletion prevents HIV Infection
- Acquired Immunity: HLA Class 1 proteins
- Key mediators of HIV progression
- Innate Protection: HLA and KIRS interactions in HIV disease
- Overview of Genome Wide Association Studies (GWAS)
- Overwhelming influence of HLA class I on HIV Progression and control of HIV viral load
- Non-HLA genetic associations with extreme phenotypes
- No new variants identified that prevent HIV infection
- Discovery of chromosome 22 associations with HIV-associated nephropathy
- Future studies
- Epigenetic, proteomic, functional studies
- Potential role of rare variants
Links
Categories:
Therapeutic Areas:
Talk Citation
Winkler, C.A. (2013, August 19). Host genetic factors that limit HIV and AIDS [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/SMMO6871.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Cheryl A. Winkler has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.